|
Market Closed -
Toronto S.E.
17:30:00 27/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0200 CAD | -.--% |
|
-.--% | -20.00% |
| Market Cap | 1.22M 883K 760K 714K 652K 84.04M 1.23M 8.46M 3.29M 42.61M 3.32M 3.24M 141M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 2.22M 1.6M 1.38M 1.3M 1.18M 153M 2.24M 15.37M 5.98M 77.39M 6.02M 5.89M 256M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| Current month | +33.33% | ||
| 1 month | +33.33% | ||
| 3 months | +33.33% | ||
| Current year | -20.00% |
| 1 week | 0.02 | 0.02 | |
| 1 month | 0.02 | 0.02 | |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.19 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 03/08/2018 |
Raylen Tamayo
DFI | Director of Finance/CFO | - | 04/05/2026 |
Mahmoud Aziz
PSD | President | - | 21/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 03/08/2018 |
Jamie Lewin
BRD | Director/Board Member | 76 | 11/03/2019 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 05/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -33.33% | -66.67% | 883K | ||
| -2.93% | +0.98% | +23.37% | +73.51% | 50.05B | ||
| +1.14% | +1.47% | +56.16% | +123.40% | 40.29B | ||
| +0.85% | +6.07% | +18.14% | +87.07% | 12.17B | ||
| +0.06% | -1.92% | -11.15% | +12.14% | 11.96B | ||
| +0.19% | -.--% | +29.35% | +150.00% | 9.25B | ||
| +0.38% | -1.13% | +25.88% | +49.35% | 7.62B | ||
| +0.17% | +3.92% | +28.93% | +223.96% | 7.36B | ||
| +1.43% | +1.70% | +45.95% | -9.99% | 7.21B | ||
| -0.84% | -2.36% | -36.62% | +16.04% | 5.26B | ||
| Average | +0.05% | +0.99% | +14.67% | +65.88% | 15.12B | |
| Weighted average by Cap. | -0.48% | +1.77% | +28.71% | +87.84% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.47 | - |
| Net income | -73.2K -52.8K -45.46K -42.68K -38.96K -5.02M -73.72K -506K -197K -2.55M -198K -194K -8.43M | -335K -242K -208K -195K -178K -23M -337K -2.32M -901K -11.66M -907K -888K -38.61M |
| Net Debt | 804K 580K 499K 469K 428K 55.19M 810K 5.56M 2.16M 27.99M 2.18M 2.13M 92.67M | 999K 721K 621K 583K 532K 68.58M 1.01M 6.91M 2.69M 34.78M 2.71M 2.65M 115M |
Employees
4,000
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















